Komori
OncoTherapy Science (4564) · RiskFirst stated

Risk of tighter regulation of therapeutic drugs, treatments and clinical research

First written in FY2018. . Latest entry: FY2018.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Uncertainty over regulatory compliance, approvals and launch delays for pharmaceuticals and regenerative medicine productsA theme 37 companies write about · 40 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2022: 3 of 16 companies on the "Worse" side.

4 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 37 companies compared. The sentences above are computed from all 37.
Full recordFilings, disclosures and news, newest first
  1. FY2018First statedAnnual report

    「The Group's business activities are affected by amendments to domestic and overseas laws and regulations and tighter regulation relating to the research and development and provision of therapeutic drugs and treatment methods, including the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, etc., the Act on the Safety of Regenerative Medicine, and the Clinical Trials Act in Japan, and regulations imposed by the FDA (U.S. Food and Drug Administration) overseas」

    The Group newly disclosed the possibility that amendments to laws and regulations and tighter regulation relating to pharmaceuticals, regenerative medicine, clinical research and overseas FDA regulations could affect its business strategy and operating results.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for OncoTherapy Science yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of tighter regulation of therapeutic drugs, treatments and clinical research | OncoTherapy Science,Inc. (4564) | Komori